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Abstract
Objective—Resuscitation of hemorrhagic hypotension after traumatic brain injury (TBI) is
challenging. A hemoglobin (Hb)-based oxygen carrier (HBOC) may offer advantages. The novel
therapeutic HBOC, polynitroxylated pegylated Hb (PNPH) may represent a neuroprotective
HBOC for TBI resuscitation.
Hypotheses—1) PNPH is a unique non-neurotoxic HBOC in neuronal culture and is
neuroprotective in in vitro neuronal injury models. 2) Resuscitation with PNPH would require less
volume to restore mean arterial blood pressure (MAP) than lactated Ringer’s (LR) or Hextend
(HEX) and confer neuroprotection in a mouse model of TBI plus hemorrhagic hypotension.
Design—Prospective randomized controlled experimental study.
Setting—University center.
Measurements and Main Results—In rat primary cortical neuron cultures, control bovine Hb
was neurotoxic (LDH release; MTT assay) at concentrations from 12.5 to 0.625µM, while
polyethylene-glycol (Peg)-conjugated Hb showed intermediate toxicity. PNPH was not neurotoxic
(p<0.05 vs bovine Hb and Peg-Hb; all concentrations). PNPH conferred neuroprotection in in vitro
neuronal injury (glutamate/glycine exposure and neuronal stretch), as assessed via LDH, and MTT
all p<0.05 vs control. C57BL6 mice received controlled cortical impact followed by hemorrhagic
hypotension (2mL/100g, MAP ~35–40 mmHg) for 90 min. Mice were resuscitated (MAP >50
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mmHg for 30 min) with LR, HEX, or PNPH, then shed blood was re-infused. MAPs, resuscitation
volumes, blood gasses, glucose and lactate were recorded. Brain sections at 7d were examined via
H&E and Fluoro-Jade C (FJC, identifying dying neurons) staining in CA1 and CA3 hippocampus.
Resuscitation with PNPH or HEX required less volume than LR (both p<0.05). PNPH but not
HEX improved MAP vs. LR (p<0.05). Mice resuscitated with PNPH had fewer FJC+ neurons in
CA1 vs. HEX and LR, and CA3 vs. HEX (p<0.05).
Conclusion—PNPH is a novel neuroprotective HBOC in vitro and in vivo that may offer unique
advantages for TBI resuscitation.
Keywords
head injury; hemoglobin based oxygen carrier; nitroxide; oxidative stress; nitric oxide;
polyethylene glycol; hemorrhagic shock; blast injury; polytrauma; blood substitute;
polynitroxylation; superoxide
INTRODUCTION
Hypotension from hemorrhage complicating traumatic brain injury (TBI) contributes to
secondary injury and poor outcome, including both morbidity and mortality. The deleterious
effects of hypotension have been demonstrated in both civilian (1) and military settings such
as blast injury (2). Effective resuscitation of combined TBI and hemorrhage is essential to
improving outcomes in the increasing numbers of individuals exposed to these combined
injuries, particularly, in military theaters abroad (3).
Traditional pre-hospital strategies for TBI resuscitation involve the administration of
isotonic fluids, such as Lactated Ringer’s (LR) solution, or colloids, such as Hextend (HEX)
(the civilian and military standards of care, respectively) after injury to restore blood
pressure, and potentially, cerebral perfusion pressure. However, large volumes of
resuscitation fluid may exacerbate cerebral edema (4), and fail to increase oxygen delivery.
In addition, these solutions fail to specifically target deleterious cascades associated with
ischemia reperfusion injury. In the pre-hospital setting, hemoglobin (Hb) based oxygen
carriers (HBOCs) may offer specific advantages over crystalloids or colloids as a
resuscitation fluid in the setting of hemorrhagic hypotension after TBI. HBOC resuscitation
may allow for volume expansion using small amounts of fluid with the potential advantage
of restoring oxygen delivery to the injured brain—which exhibits markedly increased
metabolic demands and excitotoxicity early after TBI (5). However, human clinical trials
have shown increased morbidity and mortality with the use of HBOCs (6). Current
generation HBOCs and cell-free Hb scavenge nitric oxide (NO), resulting in
vasoconstriction and decreased oxygen delivery to myocardium and other vascular beds (7).
This could also impair posttraumatic cerebral blood flow (CBF), since NO levels and
endothelial nitric oxide synthase (eNOS; NOS1) activity are compromised early after TBI in
injured brain regions (8). Additional putative deleterious side effects of HBOCs have also
been suggested. Winslow (9) proposed that increased oxygen delivery caused by free Hb
juxtaposed to vascular endothelium causes local hyperoxia with coupled vasoconstriction
which could further impair CBF in injured brain. Similarly, HBOCs and cell-free Hb can
also directly contribute to oxidative stress in both the microcirculation and parenchyma.
Specifically, extravasation of cell free Hb into tissue could result in direct cytotoxiciy and
this could be of considerable importance in TBI, since vascular disruption occurs and classic
studies have shown that cell free Hb is highly neurotoxic in cell culture (10, 11).
Chemical modification of the Hb structure has been studied to minimize the harmful side
effects of HBOCs. Nitroxyl- groups have well-known antioxidant effects including potent
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superoxide dismutase (SOD) mimetic activity, along with other favorable effects on
oxidative stress, such as limiting autoxidation (12). Polynitroxylation of Hb also creates
redox coupling between the convalently labeled nitroxides and the heme iron to provide
additional catalase mimetic activity (13). Pegylation (i.e., adding polyethylene glycol [Peg]
moieties to the Hb molecule) provides several potential favorable effects including limiting
the Hb from direct interaction with the endothelium—attenuating oxygen mediated
vasoconstriction (14) and enhancing nitrite reductase activity—with increased NO
production and blunted vasoactivity (15). Pegylation also adds a “super-colloid” effect to an
HBOC, due to the potent water scavenging effect of Peg moieties (Personal communication,
A. Abuchowski, PhD), and prolongs HBOC half life. Polynitroxylated-pegylated Hb
(PNPH) is a novel bovine HBOC developed by SynZyme Technologies that uses Prolong
Pharmaceutical’s Peg-Hb as the starting material, and thus has both of these chemical
modifications. Specifically, it has ~14 nitroxyl radicals (nitroxides) and 8–10 Peg moieties
(5KDa molecular weight each) per Hb tetramer molecule. It is prepared as a 4% Hb solution.
We recently published (16) details of a mouse model in which a mild controlled cortical
impact (CCI) injury to brain is followed by 90 min of volume-controlled hemorrhagic
hypotension resulting in an exacerbation of neuronal death in the vulnerable CA1
hippocampus vs that seen in either CCI or hemorrhage alone. Blood flow is compromised in
the hippocampus beneath the contusion during the hemorrhage. The model is perfectly
suited for exploratory evaluation of novel HBOCs in the setting of TBI resuscitation in that
it is allows for the assessment of acute hemodynamics, and long term outcome including
neuropathology. Mortality rates in the model with standard resuscitation solutions range
between 25 and 30%. Unlike large animal models, novel therapies can be explored both with
extremely small volumes of novel resuscitation fluids and with relatively limited expense.
We tested two hypotheses: 1) PNPH is a unique non-neurotoxic HBOC in neuronal culture
and is neuroprotective in in vitro neuronal injury models, and 2) Resuscitation with PNPH
would require less volume to restore mean arterial blood pressure (MAP) than LR or HEX
and confer neuroprotection in a mouse model of TBI plus hemorrhagic hypotension. In the
present communication, we present results that show that PNPH is a unique neuroprotective
Hb both in vitro and in vivo and that support its further development and evaluation as a
neuroprotective HBOC for small volume pre-hospital TBI resuscitation.
METHODS
Primary Cortical Neuronal Cultures
Primary cortical neuron-enriched cultures were prepared from the cerebral cortex of fetal
Sprague-Dawley rats (embryonic day 16). Dissociated cell suspensions were plated in 96-
well plates (5 × 104 cells/well) or in silicon dishes coated with poly-D-lysine (3 × 106). Cells
were cultured using Neurobasal medium, supplemented with B27 (Invitrogen) and
penicillin/streptomycin. The medium was changed every 2–3 days. Cells were maintained in
incubators at 37 °C in a humidified atmosphere of 5% CO2 in air. Experiments were
performed at 7–10 days in vitro. All studies in primary neuronal culture were replicated in at
least three separate experiments using primary neurons cultured from separate litters and
include assay of between 9 and 22 wells from 3 to 5 different 96-well plates.
Preparation of Hb solutions
Stroma-free bovine Hb was prepared by cross-flow ultrafiltration (UF) using a modified
published procedure (17): Fresh bovine red blood cells were purchased from Innovative
Research Novi, MI. To match with PNPH, each Hb used in the experiments was the carboxy
(CO) Hb formulation. Peg-Hb was prepared as follows. The starting material, deoxy Peg-Hb
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was obtained from Prolong Pharmaceutical Monmouth Junction, NJ, converted to carbon
monoxide ligand form as a first step, and then the Peg-Hb(CO) was diafiltrated with 8-
volumes saline using Sartoflow Alpha filtration system equipped with 50 kDa molecular-
weight cut-off membrane cassettes. PNPH was prepared as follows. The polynitroxylation
was performed by allowing Peg-Hb(CO) to react with the nitroxide compound 4-(2-
bromoacetamido)-2,2,6,6-tetramethylpiperidine-1-oxyl (BrAcTPO) which was custom
synthesized according to SynZyne’s SOP by Chunghwa Chemical Synthesis & Biotech
Company. The reaction was carried out at pH 9.0 and 37°C for 4 hours under 3-psi CO
pressure. A molar ratio of 16 nitroxides per Hb was used to start the reaction. The reaction
mixture was then ultrafiltrated with saline. Under optimum conditions, about 14 nitroxide
moieties can be covalently linked to each Peg-Hb tetramer. All samples, Hb, Peg-Hb, and
PNPH, were adjusted to 4% Hb concentration which are equivalent to 0.62 mM of tetramer
or 2.5 mM of heme as determined spectrophotometrically. MetHb was determined to be less
than 5% spectrophototmetrically. Endotoxin was determined to be less than 1 EU/ml by
Limulus Amebocyte Lysate (LAL) method. Labeled nitroxide concentration was measured
by electron paramagnetic resonance spectroscopy and the labeling number of 14 nitroxides
per Hb tetramer in PNPH was calculated from the ratio of nitroxide concentration to Hb
concentration.
Assessment of Hb-induced Neurotoxicity
The toxicity of PNPH was compared to its aforementioned parent Hb molecules,
specifically, bovine Hb and Peg-Hb in the primary neuronal culture system. For these
studies, the Hb dilutions used included 1/50, 1/100, 1/500 and 1/1000. These dilutions
yielded the following approximate Hb concentrations (expressed as the concentration of
tetramer) for the three preparations, namely 12.50 µM, 6.25 µM, 1.25 µM, and 0.625 µM,
respectively.
In Vitro Neuronal Injury Models
Glutamate/Glycine (Glu/Gly)-Induced Neuronal Death: Neurons were exposed to 10 µM L-
Glu/10 µM Gly with or without bovine Hb, bovine Peg-Hb, or PNPH in the culture medium
for 24 h. In Vitro TBI was produced by neuronal stretch (18). A computer controlled
apparatus to stretch neurons at a defined strain magnitude and rate was used. Briefly,
primary cortical neurons were grown on silicone membranes (0.002–0.005 inch thick,
Specialty Manufacturing) secured to stainless steel rings that were polished and passivated
prior to use. At 8 days in vitro (DIV), cultures were pre-treated with varying concentrations
of Hb for 30 min. The membranes were then placed over a hollowed platform in a custom-
made, sealed stainless steel chamber. The membranes were then stretched with a pre-set
strain rate (10 s−1) and membrane deformation (50%) using an air pressure pulse. The
pressure waveform is measured and collected on a data acquisition system to verify the
degree of insult. Severe stretch was chosen in order to simulate a strain field similar to that
seen in animal models of TBI (18). Neuronal cultures were then returned to the incubator.
Cultures were pre-treated with varying concentrations of Hb for 30 min. Between 6 and 8
independent stretch insults were carried out for each condition tested.
Cytotoxicity Detection (LDH release)
Cortical neuronal cell injury was quantified by the measurement of lactate dehydrogenase
(LDH) at 24 h after the insult. An aliquot of bathing media was combined with NADH and
pyruvate solutions. LDH activity is proportional to the rate of pyruvate loss, which was
assayed by absorbance change using a microplate reader (Spectra MAX 340). Blank LDH
levels were subtracted from insult LDH values, and results normalized to 100% neuronal
death caused by 0.5% Triton-100 exposure.
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Cell Viability (MTT assay)
Cell viability was evaluated using the MTT (3-[4, 5-dimethylthiazol-2-yl-]-2, 5-
diphenyltetrazolium bromide) colorimetric assay. MTT (Sigma) is a water soluble
tetrazolium salt that yields a yellowish solution when prepared in medium lacking phenol
red. Dissolved MTT is converted to an insoluble purple formazan by cleavage of the
tetrazolium ring by the active mitochondrial dehydrogenases of living cells. The MTT
solution (5 mg MTT/mL medium) was added to each well 24 h after the insult at the final
concentration of 250 µM, and incubated for 3 h. The media was removed, and cells
dissolved in DMSO. Formation of formazan was assessed by measuring the amount of
reaction product (absorbance change) using a microplate reader (Spectra MAX 340).
Groups and Experimental Protocol for In Vivo Studies
The Institutional Animal Care and Use Committee of the University of Pittsburgh School of
Medicine approved all experiments. C57BL6 male mice (Jackson Laboratories, Bar Harbor,
ME), 12–15 weeks of age, and weighing 27.7±0.5 g were housed in controlled
environmental conditions and allowed ad libitum food and water until the start of the study.
The details of this experimental model of CCI and hemorrhage have been previously
published (16).
Anesthesia was induced with isofluorane 4% in 2:1 N2O/O2 via nose cone. Femoral venous
and arterial catheters were inserted via inguinal cut-down. Animals were placed in a
stereotactic frame, a 5mm craniotomy was performed, and the bone flap removed. A brain
temperature probe (Physitemp, Clifton, NJ) was inserted into the right parietal cortex via a
burr hole. A rectal probe was inserted to monitor body temperature. Brain temperature was
controlled with a heat lamp at 37.0±0.5°C throughout the study. After the craniotomy,
anesthesia was changed to 1% isofluorane in room air for a 10 min stabilization period.
The time course of CCI and resuscitation is shown in Figure 1. CCI was performed with a
pneumatic impactor (Bimba, Monee, IL) using a flat 3-mm tip at a velocity of 5 m/s to a
depth of 1 mm. This level of injury produces a mild-moderate level of injury with no
appreciable loss of CA1 hippocampal neurons and no mortality (16). After injury, the bone
flap is replaced and the craniotomy is immediately re-sealed with dental cement and
beginning within 5 min, blood was withdrawn from the femoral arterial catheter over 15 min
to a total volume of 2.0ml/100g, a volume shown to produce a MAP between ~35–40
mmHg (Hemorrhage phase). Shed blood was stored for later infusion. This phase continued
for 90 total min (75 min after the completion of blood withdrawal).
Mice were then resuscitated with 0.1 mL aliquots of LR, HEX (Hospita, Lake Forest, IL), or
PNPH to a goal MAP ≥ 50 mmHg for 30 min duration (Pre-hospital phase). Mice continued
to receive 1% isofluorane with room air for anesthesia. At the conclusion of this phase, mice
were switched to isofluorane 1% in oxygen and shed blood was rapidly re-infused
(Definitive Care phase). After the shed blood was re-infused, a goal MAP ≥ 60 mmHg was
obtained by administration of additional resuscitation fluid given in 0.1-mL aliquots, if
necessary. Total volume of resuscitation fluid administered in each phase was recorded.
After the completion of the Definitive Care phase, catheters were removed, incisions were
closed, anesthesia was discontinued, and mice were placed in supplemental oxygen until
they were recovered from anesthesia at which time they were then returned to their cage.
Monitoring
Arterial blood pressure was continuously monitored via femoral venous cannula. Heart rate
was monitored continuously and was recorded every 5 min. Arterial blood gasses were
obtained at baseline, 30 min after hemorrhage, Post-resuscitation and at the end of the
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Definitive Care phase. Evaluation of hematocrit, arterial lactate, and blood glucose was also
performed at these time points.
Histology
At 7 days post-injury, animals were anesthetized with 4% isofluorane and killed by
transcardial perfusion fixation with ice-cold saline followed by 10% buffered formalin.
Brain tissue was fixed with 10% buffered formalin and embedded in paraffin. Multiple 5µm
sections, 200µm apart from bregma −1.86 to −2.26, were prepared from each brain. Sections
were stained with Fluoro-Jade C (FJC; Chemicon, Temecula, CA) and hematoxylin and
eosin (H&E; Thermo Scientific, Pittsburgh, PA), and hippocampal neuronal degeneration
was quantified in the dorsal CA1 and CA3 hippocampus underlying the cortical contusion in
brain sections stained with FJC by an evaluator blinded to treatment group using ImageJ
software (NIH). The number of surviving neurons in CA1 and CA3 were also quantified by
a blinded observer in the H&E-stained sections.
Statistical Analysis
Data are expressed as mean ± SEM or median [range] where appropriate. Analysis of
variance was used to compare continuous physiologic variables between groups.
Appropriate post-hoc analysis was performed including Student-Neuman-Keuls or Tukey
test when a significant ANOVA result was discovered. Kruskal-Wallis non-parametric
analysis was used to determine the significance of non-parametric data.
RESULTS
In Vitro Studies
Hb toxicity studies—Exposure of neurons to bovine Hb produced anticipated
neurotoxicity based on prior reports (10), and neurotoxicity was seen at all concentrations
and dose dependent as assessed by either LDH or MTT assays (Figures 2 and 3). Based on
LDH release, a significant dose response (a ~20–40% cell loss relative to Triton lysis) was
observed across concentrations for bovine Hb, with the 1:50 dilution showing significant
neuronal death vs all other concentrations (p<0.05, Figure 2). In the MTT assay, native
bovine Hb also showed a dose response for toxicity with the greatest loss of neuronal
viability at the highest two concentrations (again p<0.05, Figure 3). Peg-Hb was also
neurotoxic, but less (p<0.05) than native bovine Hb at the two highest concentrations in the
LDH assay, and across all concentrations in MTT assay (Figures 2 and 3). Remarkably,
PNPH was devoid of any neurotoxicity as assessed with either LDH or MTT assays across
all concentrations. In both the LDH and MTT assays, all PNPH concentrations were
different (p<0.05) from both bovine Hb and Peg-Hb at all concentrations studied (Figures 2
and 3).
In Vitro Neuronal Injury Models
PNPH also attenuated Glu/Gly-induced neuronal death at all concentrations as determined
by LDH and MTT assays (p<0.05, Figures 4 and 5). The reduction in LDH release by PNPH
after Glu/Gly exposure was similar to baseline LDH release in normal neurons in our
preparation (Figure 4). Native bovine Hb, at the highest two concentrations further reduced
neuronal viability after Glu/Gly as assessed in the MTT assay (Figure 5). Native bovine Hb
reduced LDH release induced by Glu/Gly, but only at 0.625 µM (Figure 4). Bovine Peg-Hb
did not exacerbate neuronal death induced by Glu/Gly, and in fact showed intermediate
attenuation of Glu/Gly toxicity assessed by MTT and LDH assays (Figures 4 and 5). The
effect of the three Hb preparations was also assessed in the neuronal stretch model at the
1.25µM concentration with cell death assessed again using both the LDH and MTT assays at
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24 h (Figures 6A–B). In the stretch model, between 30 and 40% neuronal death was
observed (by both assays). Neuronal death from stretch was significantly exacerbated by
exposure to native bovine Hb (p<0.05 vs stretch alone by both LDH and MTT assays). Peg-
Hb modestly reduced neuronal death vs stretch alone in the LDH but not MTT assay, while
a marked reduction in neuronal death was produced by PNPH (to ≤12% in both LDH and
MTT assays, p<0.05 vs all stretch injury groups including stretch plus Peg-Hb).
In Vivo Experimental TBI plus Hemorrhagic Hypotension in Mice
To obtain n=5 survivors in each of the three groups, a total of 20 mice were used. A total of
n=6 animals were resuscitated with PNPH, n=5 mice were resuscitated with HEX, and n=9
mice were resuscitated with LR. The trend toward higher mortality in the LR group did not
reach significance.
Physiology—Table 1 provides a summary of the resuscitation volume delivered during the
Pre-hospital phase of the experiment and the mean and peak MAPs resulting in each phase
of the experiment. Resuscitation with PNPH and HEX required less volume than LR (p <
0.0001 for PNPH vs. LR and p≤ 0.05 for HEX vs LR). When expressed in volume per
kilogram dose, PNPH, HEX, and LR treated groups required 6.7 ± 1.8 mL/kg, 9.6 ± 2.6 mL/
kg, and 36.3 ± 11.5 mL/kg, respectively.
Before resuscitation, all three groups had similar initial MAPs (p=0.61). Each group had
similar mean and peak MAPs during the Hemorrhage phase (p=0.42 mean MAP, p=0.61
peak MAP). The mean MAP for each group during the Hemorrhage phase was within a
target range of 30–40 mmHg and no differences were detected between groups (p=0.61).
During the Pre-hospital phase, all groups attained mean MAPs greater than 50 mm Hg.
However, the PNPH and HEX groups attained mean MAPs significantly greater than the LR
group (p<0.05 for both PNPH vs. LR and HEX vs. LR). Peak MAPs were also higher in the
PNPH group vs LR (p< 0.05), but did not differ vs HEX. Mice resuscitated with PNPH
reached goal MAPs by 5 min into the Pre-hospital phase (Figure 7), while mice in the HEX
and LR groups took between 10 and 15 min despite ongoing fluid administration. After the
initial difference between groups at 5 min, mice in the PNPH group trended towards higher
MAP vs both HEX and LR until 25 min into the Pre-hospital phase when the mean MAPs
were statistically higher. During the Definitive Care phase, which began after reinfusion of
shed blood, the mean MAPs between groups were not different (p=0.19). However, the
PNPH group attained higher peak MAPs during the 30 min Definitive Care phase than HEX
(p<0.05 for PNPH vs. HEX).
Table 2 provides a summary of hematocrit, lactate, base deficit, and glucose levels
throughout the study. In all groups, the hematocrit decreased significantly from baseline
values to the Hemorrhage phase (p<0.05). Pre-hospital resuscitation with PNPH, HEX, and
LR resulted in post-resuscitation hematocrit values that trended lower than, but were not
different from values in the Hemorrhage phase. Infusion of shed blood in the Definitive Care
phase appropriately yielded a rise in hematocrit from Post-Resuscitation values in all groups,
but resulted in hematocrits still lower than baseline values (p<0.05). There were no between
group differences in hematocrit noted in any of the phases. There were also no between
group differences in lactate levels, though the lactate did decrease in each group in the
Definitive Care phase vs earlier phases. There was a significant difference in base deficit in
LR treated mice vs baseline during hemorrhage, but there were no differences between
treatment groups during hemorrhage, and the effect was extremely small and unlikely to be
physiologically significant. Glucose levels were also similar between groups at all points
during the experiment. Though there was a trend towards lower glucoses in the Post-
Resuscitation and Definitive Care phases, these levels did not reach statistical significance.
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Table 3 summarizes pH, PaCO2, and PaO2 values during the study. There was no significant
change in pH during the study phases or difference between groups. In the each group, there
was a significant rise in PaCO2 between the Hemorrhage and Definitive Care phases and
between the Post-Resuscitation time point and the Definitive Care phase. There was a
significant decrease in the PaO2 across groups between the Baseline measurements and the
Hemorrhage phase. There was also a significant increase in PaO2 in all groups between the
Post-Resuscitation time point and the Definitive Care phase values as expected with the
increase in FiO2 from 0.21 to 1.0.
Neuropathology—Hippocampal sections taken from mice resuscitated with LR and HEX
in our combined injury model typically exhibited a focal area of neuronal degeneration in
the CA1 region of the hippocampus at 7 d after the insult as reflected by FJC staining
(Figure 8). As anticipated, FJC-positive neurons were markedly greater in CA1 than in CA3
in this model (16). However, the number of FJC positive neurons found in CA1 was
significantly less in mice resuscitated with PNPH (median 3, range [0–6]) than those
resuscitated with HEX (18, [7–48]) or LR (21, [4–34]) (p<0.05). Mice resuscitated with
PNPH (0, [0–1]) also had fewer FJC positive neurons in CA3 compared to HEX (12; [0–
15]) (PNPH vs. HEX, p<0.05)
Hippocampal sections taken from mice resuscitated with LR and HEX typically exhibited
thinning of the hippocampus as well as a focal area of neuronal death, as noted in H&E-
stained sections by the defect in the contour in the CA1 region of the hippocampus (Figure
9). Sections taken from those animals resuscitated with PNPH showed little evidence of
neuronal eosinophilia with pyknotic nuclei indicative of the typical injury to CA1 seen in
this model. The linear density of neurons in CA1 (Figure 10) did not significantly differ
between groups: PNPH median 18.95 cells/0.1 mm [13.08–20.82 cells/0.1mm] vs. HEX
14.23 cells/0.1mm [7.79–17.42 cells/0.1mm] vs. LR 13.58 [8.13–17.97 cells/0.1mm]
(p=0.16). There was no significant effect of the resuscitation fluid on neuronal survival in
CA3: PNPH 9.34 cells/0.1mm [7.57–9.80 cells/0.1mm] vs. HEX 9.04 cells/0.1mm [8.15–
10.04 cells/0.1mm] vs. LR 8.89 cells/0.1mm [7.68–9.74 cells/0.1mm]. The degree of injury
seen on H&E staining in HEX and LR groups is comparable to our prior report in this model
(16).
DISCUSSION
This study is the first to examine PNPH as a therapeutic HBOC. Based on our work in in
vitro models, we report that unlike native Hb, PNPH exhibits a unique lack of neurotoxicity
as assessed with multiple assays of cell viability in rat primary neuronal culture, and
surprisingly, PNPH is neuroprotectve in in vitro models of both excitotoxicity and TBI
(neuronal stretch). In vivo, using an established murine model of TBI plus hemorrhagic
hypotension (16, 19), the use of a PNPH solution as a resuscitation fluid, like the colloid
HEX, conferred an advantage over LR as being a small volume resuscitation solution, but
PNPH also produced a potentially more favorable hemodynamic response than either LR or
HEX. Importantly, mirroring the in vitro studies, PNPH produced unique neuroprotection in
selectively vulnerable CA1 beneath the contusion in our model. Each of these effects
deserves further discussion.
Specific properties of PNPH
The PNPH used in these studies is a covalently modified (polynitroxylated) version of a
well-characterized bovine Peg-Hb (Prolong) (20). It has a P50 of 11 and it contains ~14
nitroxide moieties and 8–10 Peg moieties that are covalently linked. It is prepared as a 4%
solution. Based on a formulation containing a 4% solution, it is being developed as a small
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volume, antioxidant, neuroprotective resuscitation fluid, rather than a current generation
blood replacement therapy. With regard to in vivo resuscitation, LR, HEX, and PNPH have
an osmolarity of 273, 307, and ~308, respectively.
Lack of neurotoxicity of PNPH in vitro
As anticipated, native bovine Hb showed dose-dependent neurotoxicity in our in vitro
system (10, 11). Neurotoxicity was blunted by pegylation, although it was still evident at all
concentrations for Peg-Hb. In contrast, PNPH was devoid of neurotoxicity across
concentrations and assays in our culture system. Regan and Panter (10) reported dose
dependent neurotoxicity (LDH release) in a mixed cortical culture containing both neurons
and glia exposed to purified human Hb concentrations between 0.025 and 25 µM (based on
the tetramer) for 24–48 h. Supporting a key potential role for oxidative injury, neurotoxicity
was markedly attenuated by the antioxidant Trolox, the 21-aminosteroid U745000A, or the
iron chelators deferoxamine or phenanthroline (10, 21). Oxidative damage to the erythrocyte
cell membrane or membrane bound enzymes was suggested to mediate these findings, and
iron release from Hb may be important (22). We noted similar results for bovine Hb at
concentrations of 0.625 – 12.50 µM (based on the tetramer) at 24 h exposure. Thus,
neurotoxicity of Hb may be abrogated by PNPH via its covalently linked nitroxides, which
confer SOD mimetic effects and other antioxidant actions. However, based on our data,
pegylation also partially blunts the neurotoxicity. Thus other effects such as accessibility or
stability of the Hb moiety could also contribute to this favorable effect of PNPH. The unique
lack of neurotoxicity of PNPH could be quite important in TBI resuscitation if an HBOC is
contemplated as a therapy since blood-brain barrier (BBB) damage and hemorrhage are
well-known complications of TBI and thus resuscitation with a conventional cell free Hb
could cause direct neurotoxicity locally in the injured brain.
In vitro neuroprotection by PNPH
Based on prior work (11), we did not anticipate dramatic augmentation of glutamate-
mediated neuronal death by the Hb preparations that we examined. Minimal increases in
LDH release by human Hb were seen in mixed murine neuron and glial cultures exposed to
the excitotoxic agent N-methyl-D-aspartate (NMDA) at a 9 µM concentration. Our data with
Glu/Gly exposure at 10 µM also suggest only modest augmentation of excitotoxic neuronal
death by bovine Hb at the highest concentrations tested. We were, however, surprised that
PNPH was neuroprotective against Glu/Gly toxicity at all concentrations and that even Peg-
Hb showed some protection. Although the mechanisms underlying the neuroprotective
effect of PNPH remain to be defined, oxidative damage is a key facet of excitotoxicity.
Relevant to protection by PNPH, excitoxic injury was recently shown to involve a critical
role for neuronal membrane bound NADPH oxidase-mediated oxidative damage (23). Since
PNPH would be expected to be confined to the extracellular space, this is an attractive
target. Redox effects directly on the NMDA receptor could also reduce excitotoxicity (24).
Finally, since Peg-Hb conferred intermediate neuroprotection, other effects could be
operating. PNPH also showed protection in the in vitro TBI model system as shown again
using both LDH and MTT assays. Given our results in the Glu/Gly model, this finding might
be anticipated since excitotoxicity plays a major role in mediating neuronal death in the
stretch model (18).
Small volume resuscitation effects of PNPH on hemodynamics
PNPH required significantly less volume than LR to achieve target MAP in mice subjected
to TBI plus hemorrhage. PNPH required ~1/5th of the volume as LR, while HEX required
~1/3rd the volume as LR. Small volume resuscitation with HEX or HBOCs may be quite
effective in the setting of acute hemorrhage after TBI (25–27). However, the ability to
consistently maintain the pre-hospital target MAP of 50 mmHg was better with PNPH than
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with either LR or HEX—even when using this conservative MAP goal. The ability of an
HBOC to more rapidly achieve a target MAP of 50 mmHg, however, could be viewed as
either beneficial or detrimental. Small volume resuscitation after TBI confers protection
against the development of brain edema and intracranial hypertension (4). Better recovery of
MAP could be beneficial by more promptly restoring CBF if cerebral perfusion pressure
(CPP) is below the autoregulatory limit, or if blood pressure autoregulation of CBF is
impaired, which is common after TBI (28). However, in the setting of polytrauma with
uncontrolled bleeding, the target MAP may need to be conservative to limit bleeding (29).
We chose a MAP of 50 mmHg in the pre-hospital phase to simulate a clinical scenario
where ongoing bleeding outside of the brain might limit the ability to attain a “normal”
MAP while providing the lowest acceptable MAP for cerebral perfusion. Also, scavenging
of NO by an HBOC could lead to inappropriate vasoconstriction that could compromise
both systemic recovery from hemorrhage and CBF (7). Our findings, however, argue against
this possibility since PNPH did not worsen Post Resuscitation lactate or pH and also
produced neuroprotection, unlike either LR or HEX. Potentially favorable properties related
to pegylation could play a role in mediating some of the observed hemodynamic effects of
PNPH. Pegylation of proteins confers “supercolloid” effects. Theoretically, each strand of
PEG binds 132 molecules of water (personal communication, A. Abuchowski), thus each
PNPH molecule can potentially bind >1000 water molecules. This would be anticipated to
provide significant oncotic advantages to PNPH and Peg-Hb vs either HEX, which is
generally felt to have oncotic effects similar to 5% albumin (30, 31), or the crystalloid LR.
This could attenuate brain edema while expanding vascular volume. Thus, our data suggest
that for a reasonable, albeit conservative, target pre-hospital MAP, resuscitation with PNPH
confers important advantages over LR or HEX.
Neuroprotective effects of PNPH in vivo
We observed neuroprotection by PNPH resuscitation at 7 d after injury that was not seen
with either LR or HEX. We previously examined resuscitation with LR, HEX, or 3% saline
in this model and none of these solutions conferred neuroprotection in CA1 (19). Our
current report confirms this finding for both LR and HEX. Several other studies have shown
beneficial effects of HBOC-201 based resuscitation on CPP, ICP, brain edema, brain tissue
oxygen levels, and neuropathology in pig models of TBI plus hemorrhage (25–27). Unique
in our studies in mice is the assessment of neuropathology at a 7 d after injury. Studies in
large animal models have focused on very short-term outcomes (generally 6–8 h), and it has
long been known that ischemia-induced neuronal death in CA1 can be delayed, often
beyond 2 d (32). We observed neuroprotection by PNPH in the hippocampus which is
beneath the contusion and may represent a penumbra in the injured hemisphere. It is a
region where the BBB is disrupted (33) and where there would be concerns over HBOC
extravasation into injured brain. In contrast, prior reports with other HBOCs in large animal
models have seen protection limited to sites remote from the impact (27).
The neuroprotection could be partially explained by the improved MAP seen in mice
resuscitated with PNPH vs HEX or LR. However, since both PNPH and HEX represented
small volume resuscitation solutions in our model but only PNPH conferred
neuroprotection, limitation of volume administration alone cannot explain the observed
benefit. Nevertheless, the ability of PNPH to promptly and consistently achieve the target
pre-hospital MAP of 50 mmHg may prevent a cascade of secondary injury.
PNPH may facilitate oxygen delivery to the hippocampus beneath the contusion. However,
the amount of oxygen carrying capacity from ~6 mL/kg of a 4% PNPH solution during
resuscitation is modest when compared to the amount of Hb lost via hemorrhage in our
model (~30% blood volume). The P50 of 11 (although lower than the normal P50 of ~28 for
Hb in erythrocytes) is relatively high for an HBOC (6). The ability of HBOCs to approach
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the vascular endothelium can yield greater than anticipated oxygen delivery. A 500 mL
infusion of the non-nitroxylated parent PEG-Hb (Prolong) formulation used in our studies
substantially improved oxygen delivery in a pig model of hemorrhagic shock (20). It is thus
possible that some of the neuroprotection afforded by PNPH is related to enhanced cerebral
oxygen delivery. We are currently examining hippocampal brain tissue PO2 during PNPH
resuscitation.
PNPH also contains ~14 nitroxide moieties that provide antioxidant and SOD mimetic
effects. Free nitroxides exhibit neuroprotective effects in experimental TBI. Zhang et al (12)
reported a reduction in brain edema and BBB permeability in a rat model of TBI by
treatment with Tempol. Deng-Bryant et al (34) reported that Tempol attenuated
neurodegeneration after CCI in mice as assessed with silver staining. Leker et al (35)
showed benefit from Tempol in experimental stroke. Further supporting a role of the
nitroxides of PNPH, a polynitroxylated albumin solution reduced vascular injury in models
of ischemia reperfusion (36, 37), conferred neuroprotection in stroke in rats (38), and
improved survival in experimental hemorrhage (39). PNPH, by reducing superoxide may
limit NO loss to peroxynitrite formation. This would confer a dual benefit—limiting NO
consumption and attenuating peroxynitrite production. One might not expect that antioxidant
moieties decorating a large molecule like Hb could contribute to neuroprotection in
parenchyma. However, our in vitro data argue strongly against that premise. Further studies
are needed to define the effects of PNPH on oxidative stress in our models.
Finally, the PNPH used in these studies was a carboxy (CO) Hb PNPH formulation. Carbon
monoxide (CO) protects the Hb iron during the synthetic addition of the nitroxide moieties.
CO inhalation confers cytoprotection in several model systems, possibly via effects on P38
kinase or oxidative stress (40). Koehler et al (41), in preliminary studies, reported that CO
Hb levels increase to ~5% after a 20 mL/kg topload with PNPH and then decrease back to
baseline over ~2h in rats. This suggests that PNPH may deliver CO to injured brain early in
resuscitation. This would also argue that PNPH is unlikely to confer direct neuroprotection
via enhanced oxygen delivery, at least during the pre-hospital phase. It has been shown;
however, that unlike inhalation of CO, transfusion of blood with high levels of CO to dogs
does not produce toxicity (42). The possible role of CO in mediating the neuroprotective
effects of PNPH in TBI merits additional study.
Unique aspects of resuscitation in the setting of TBI plus hemorrhage
Free Hb binding to NO at the endothelium produces vasoconstriction and systemic
hypertension (7). Deleterious effects of current generation HBOCs in humans likely result
from coronary artery constriction via this mechanism. Studies have investigated the delivery
of inhaled NO or other vasodilators during HBOC use to prevent vasoconstriction (43).
However after TBI, some vasopressor action may be tolerated or even advantageous. The
use of pressors after TBI may minimize resuscitation fluid volume (44). Use of large fluid
volumes during resuscitation may exacerbate brain edema. Though the use of pressors in the
setting of hemorrhagic shock is controversial, a resuscitation fluid with some intrinsic
vasopressor action may limit fluid volumes and brain edema.
Limitations of the study
We recognize that cell culture systems do not include a number of endogenous antioxidant
defenses that are present in brain tissue (10). In our in vivo studies, although we showed
benefit of PNPH on both hemodynamics and neuroprotection, there are several limitations.
We focused on acute hemodynamics and 7 d neuropathology. We are currently assessing
other outcomes including brain tissue oxygen, intracranial pressure, BBB, CBF, and
behavior. It is also not clear what the optimal target MAP is in TBI plus hemorrhage (45).
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The chosen target MAP of 50 mmHg is reasonable, but other targets could yield different
results. We did not re-infuse shed blood until completion of the pre-hospital phase to
maximize clinical relevance and we recognize that the effect of immediate resuscitation with
blood was not explored. Effects of volatile anesthetics such as isoflurane could influence the
target MAP after TBI and neuroprotection (46), however it is the most commonly used
anesthetic in experimental TBI (47). We did not monitor total Hb levels in this exploratory
study with PNPH. Currently, using a similar protocol we noted that 20 mL/kg of 4% PNPH
does not appreciably increase total Hb levels, suggesting that it is unlikely that use of only
~6–7 mL/kg of PNPH in this study would significantly increase arterial Hb level. This may
also be related to plasma volume expansion produced by the Peg moieties. We noted greater
neuroprotection assessed by FJC staining than with H&E, which may be related to greater
sensitivity of FJC in assessing damage. Blood glucose levels were generally in the low
normal range and a hyperglycemic response was not observed. However, glucose levels did
not differ between groups. We used room air during the pre-hospital phase. Use of
supplemental oxygen could alter the efficacy of an HBOC. Given that this work was
supported by the United States Army, we chose to simulate the combat casualty care
scenario where oxygen is not used in the field due to tactical factors.
CONCLUSIONS
PNPH is a unique non-neurotoxic therapeutic HBOC with novel neuroprotective effects in
both in vitro and in vivo TBI models. Limited fluid resuscitation of TBI plus hemorrhagic
hypotension in mice using PNPH offers advantages over LR or HEX including better
normalization of MAP, and neuroprotection. The mechanisms underlying the
neuroprotection produced by PNPH deserve further exploration.
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Figure 1.
Diagram depicting the time course of the experimental protocol used in this study (CCI,
controlled cortical impact; TBI, traumatic brain injury; CCI, controlled cortical impact;
MAP, mean arterial blood pressure, ABG, arterial blood gas.
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Figure 2.
Effect of various hemoglobins (Hbs) on lactate dehydrogenase (LDH) release from primary
rat cortical neurons in culture. Hbs were added to the culture medium for 24 h at
concentrations (based on the tetramer) ranging between 0.625 µM and 12.50 µM. Percent
cytotoxicity (LDH release) relative to Triton exposure (corrected for background LDH) is
graphed. Native bovine Hb (Hb) showed dose-dependent neurotoxicity. Polyethylene glycol
(Peg) conjugated bovine Hb (Peg-Hb) showed less toxicity than native Hb while
polynitroxylated pegylated Hb (PNPH) was devoid of neurotoxicity across all
concentrations tested. Data are mean ± SEM from at least three separate experiments and
include assay of between 9 and 30 wells from between 3 and 5 different 96 well
plates. ap<0.05 vs all Hb and Peg-Hb values at all dilutions; bp<0.05 vs Hb values at the
12.50 and 6.25 µM concentrations; cp<0.05 vs Hb at 12.50 µM concentration; dp<0.05 vs Hb
at 6.25µM concentration.
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Figure 3.
Effect of various hemoglobins (Hbs) on cell viability assessed with the MTT assay in
primary rat cortical neurons in culture. Hbs were added to the culture medium for 24 h at
concentrations ranging between 0.625 µM and 12.50 µM. MTT as a percent of baseline is
shown. Native bovine Hb (Hb) showed dose-dependent neurotoxicity with reduced neuronal
viability. Polyethylene glycol (Peg) conjugated bovine Hb (Peg-Hb) showed less toxicity
than native Hb while polynitroxylated pegylated Hb (PNPH) was devoid of neurotoxicity
across all concentrations tested. Data are mean ± SEM from at least three separate
experiments and include assay of between 9 and 30 wells from between 3 and 5 different 96
well plates. ap<0.05 vs all Hb and Peg-Hb values at all concentrations; bp<0.05 vs Hb values
at all concentrations; cp<0.05 vs Hb at 12.50 µM and 6.25 µM concentrations.
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Figure 4.
Effect of various hemoglobins (Hbs) on lactate dehydrogenase (LDH) release in a primary
rat cortical neuron culture model of glutamate/glycine (Glu/Gly)-induced excitotoxicity. The
test Hb was added to the culture medium and 30 min later Glu/Gly (10 µM) exposure was
begun and continued for 24 h. Hb concentrations ranged between 0.625 µM and 12.50 µM.
Percent cytotoxicity (LDH release) relative to Triton exposure (corrected for background
LDH) is graphed. PNPH showed surprising neuroprotection at all Hb concentrations. Peg-
Hb showed intermediate protection, while native bovine Hb (Hb) was not neuroprotective.
Data are mean ± SEM from at least three separate experiments and include assay of between
9 and 30 wells from between 3 and 5 different 96 well plates. ap<0.05 vs Glu/Gly and both
respective Hb and Peg-Hb value; bp<0.05 vs Glu/Gly and respective Hb value; cp<0.05 vs
Glu/Gly value.
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Figure 5.
Effect of various hemoglobins (Hbs) on cell viability (MTT assay) in a primary rat cortical
neuron culture model of glutamate/glycine (Glu/Gly)-induced excitotoxicity. The test Hb
was added to the culture medium and 30 min later Glu/Gly (10 µM) exposure was begun and
continued for 24 h. Hb concentrations ranged between 0.625 µM and 12.50 µM. MTT as a
percent of baseline is graphed. PNPH showed surprising neuroprotection at all Hb
concentrations. Peg-Hb showed intermediate protection, while native bovine Hb (Hb)
exacerbated Glu/Gly toxicity reducing neuronal viability at the highest concentrations. Data
are mean ± SEM from at least three separate experiments and include assay of between 9
and 30 wells from between 3 and 5 different 96 well plates. ap<0.05 vs Glu/Gly and both
respective Hb and Peg-Hb value; bp<0.05 vs Glu/Gly and respective Hb value; cp<0.05 vs
Glu/Gly value.
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Figure 6.
A–B. Effect of bovine Hb, Peg-Hb and PNPH (1.25 µM) on rat cortical neurons in culture
exposed to in vitro trauma by neuronal stretch. The test Hb was added to the medium and 30
min later neuronal stretch was induced. A) % cytotoxicity (LDH release) relative to Triton
exposure (corrected for background LDH). Stretch produced ~34% neuronal death at 24 h
assessed by LDH. PNPH showed surprising neuroprotection. Peg-Hb showed intermediate
protection, while native bovine Hb exacerbated neuronal death after stretch. Data are mean +
SEM from 6–8 separate experiments and include assay of 18–22 wells for each Hb. ap<0.05
vs stretch; bp<0.05 vs native bovine Hb value; cp<0.05 vs Peg-Hb value. B) MTT as %
baseline. Stretch again produced ~35% neuronal death at 24 h by MTT. PNPH again showed
surprising neuroprotection. Peg-Hb showed no neuroprotection by MTT, while native
bovine Hb again exacerbated neuronal death induced by stretch. Data are mean + SEM from
6–8 separate experiments and include assay of 18–22 wells for each Hb. ap<0.05 vs
stretch; bp<0.05 vs bovine Hb value; cp<0.05 vs Peg-Hb value.
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Figure 7.
Time course of the response in mean arterial pressure to resuscitation fluid administered
during the 30 min Pre-hospital resuscitation phase for each group. Time points 0 min and 30
min below correspond to experiment time 90 min to 120 min, respectively, in Figure 1. Data
indicate mean ± SEM at each time point, n=5 per group. (* p<0.05, ANOVA)
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Figure 8.
Photomicrographs of representative sections of CA1 stained with Fluoro-Jade C depict
degenerating neurons in mice resuscitated with (A) PNPH, (B) HEX, or (C) LR. Scatter plot
(D) of number of FJC positive neurons in both CA1 and CA3 for each group with median
represented by solid bar. (p<0.05, post hoc Tukey test vs. *HEX, and †LR)
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Figure 9.
Photomicrographs (20× objective) of Hematoxylin and Eosin stained representative sections
of CA1 hippocampus in mice resuscitated with (A) PNPH, (B) HEX, and (C) LR. Dark
arrows mark focal deficits seen in multiple sections of mice treated with HEX and LR, but
not those treated with PNPH.
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Figure 10.
Scatter plot showing density of viable neurons stained with H&E in CA1 and CA3 for each
group with median represented by solid bar. There were no significant differences between
groups.
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Table 1
Physiologic Data (Resuscitation Volume, Mean Arterial Pressures)
PNPH HEX LR
Resuscitation Volume (mL) 0.18±0.03* 0.26±0.04* 0.98±0.16
Initial MAP (mmHg) 79.3±1.7 76.4±2.9 78.3±1.4
Mean Hemorrhage Phase MAP (mmHg) 35.5±1.8 39.2±2.2 37.8±1.6
Peak Hemorrhage Phase MAP (mmHg) 43.8±2.9 48.2±3.4 46.5±2.6
Mean Pre-hospital Phase MAP (mmHg) 64.4±1.5*† 58.8±1.5* 50.5±1.7
Peak Pre-hospital Phase MAP (mmHg) 73.5±2.0* 65.8±3.2* 58.0±2.2
Mean Definitive Care Phase MAP (mmHg) 73.5±2.6 67.9±1.9 69.4±1.7
Peak Definitive Care Phase MAP (mmHg) 83.6±3.4*† 73.0±1.8 76.0±1.7
*p<0.05 vs. LR,
†p<0.05 vs. Hex
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Table 2
Physiologic Data (Hematocrit, Lactate, Base Deficit, Glucose) at defined time points in the experimental
protocol
Baseline Hemorrhage Post-resuscitation Definitive Care
Hematocrit (%)
     PNPH 37.5±0.4 25.8±1.8* 23.3±1.2* 27.7±0.6*
     HEX 37.4±0.6 28.2±0.9* 23.0±1.2* 28.2±0.7*
     LR 37.9±0.5 27.6±1.3* 22.5±1.0* 29.6±0.8*
Lactate (mmol/L)
     PNPH 2.6±0.1 2.4±0.2 2.6±0.2 1.8±0.1*‡
     HEX 2.9±0.2 2.6±0.2 2.5±0.2 1.9±0.1*
     LR 2.8±0.2 2.7±0.2 3.0±0.5 1.7±0.1‡
Base Deficit (mmol/L)
     PNPH 4.9±0.8 7.0±0.8 6.2±0.7 6.2±0.9
     HEX 4.1±0.4 5.7±0.4 5.0±0.3 4.7±0.4
     LR 4.4±0.4 6.2±0.4* 5.9±0.5 5.8±0.4
Glucose (mg/dL)
     PNPH 78.3±4.7 70.3±9.5 53.8±5.7 56.5±2.7
     HEX 89.5±4.2 81.8±7.4 62.4±1.6 59.4±2.2
     LR 90.6±10.9 92.6±9.1 72.3±7.1 55.9±2.7*†
*p<0.05 vs Baseline,
†p<0.05 vs. Hemorrhage,
‡p<0.05 vs. Post-resuscitation
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Table 3
Physiologic Data (pH, PaCO2, PaO2) at defined time points in the experimental protocol
Baseline Hemorrhage Post-resuscitation Definitive Care
pH
     PNPH 7.38±0.01 7.39±0.02 7.40±0.03 7.32±0.02
     HEX 7.38±0.01 7.40±0.02 7.42±0.01 7.35±0.01
     LR 7.39±0.01 7.40±0.01 7.40±0.02 7.35±0.01
PaCO2 (torr)
     PNPH 31.7±1.1 27.0±1.8 27.2±1.2 35.6±2.0†‡
     HEX 32.9±1.8 28.0±2.0 27.5±1.2 35.2±1.8†‡
     LR 31.9±1.0 27.0±1.2 28.3±1.3 33.3±1.5†‡
PaO2 (torr)
     PNPH 164.2±3.3 93.0±4.3* 87.8±4.4*† 444.9±3.7*†‡
     HEX 161.3±4.8 92.7±5.5* 87.4±5.6*† 447.2±1.2*†‡
     LR 157.6±3.5 97.3±3.1* 86.8±3.9*† 446.4±10.7*†‡
*p<0.05 vs Baseline,
†p<0.05 vs. Hemorrhage,
‡p<0.05 vs. Post-Resuscitation
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